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Our previous research showed that poly(vinyl alcohol) (PVA) nanoparticles incorporating DNA with hydrogen bonds obtained
by high hydrostatic pressurization are able to deliver DNA without any signiﬁcant cytotoxicity. To enhance transfection
eﬃciency of PVA/DNA nanoparticles, we describe a novel method to prepare PVA/DNA nanoparticles encapsulating nanoscaled
hydroxyapatites (HAps) prepared by high hydrostatic pressurization (980MPa), which is designed to facilitate endosomal
escape induced by dissolving HAps in an endosome. Scanning electron microscopic observation and dynamic light scattering
measurement revealed that HAps were signiﬁcantly encapsulated in PVA/HAp/DNA nanoparticles. The cytotoxicity, cellular
uptake, and transgene expression of PVA/HAp/DNA nanoparticles were investigated using COS-7 cells. It was found that, in
contrast to PVA/DNA nanoparticles, their internalization and transgene expression increased without cytotoxicity occurring.
Furthermore, a similarlevel of transgene expression between plasmid DNA and PVA/HAp/DNA nanoparticles was achieved using
in vivo hydrodynamic injection. Our results show a novel method ofpreparing PVA/DNA nanoparticles encapsulatingHAp nano-
crystals by using high hydrostatic pressure technology and the potential use of HAps as an enhancer of the transfection eﬃciency
of PVA/DNA nanoparticles without signiﬁcant cytotoxicity.
1.Introduction
Polymeric gene delivery systems are of great interest in gene
therapy because of their greater degree of safety compared to
that of viral vectors. Many types of cationic polymers, such
as poly-L-lysine and its derivatives [1, 2], polyethyleneimine
[3], polyamidoamine dendrimer [4], and vinyl polymers [5],
have been developed as gene carriers to aim at eﬀective and
safe in vitro and in vivo gene transfection into cells. They can
spontaneously condense DNA by electrostatic interaction
between positive charged groups of polycation and phos-
phate groups of DNA and form complexes, which are called
polyplexes. The polyplex formation protects DNA from
degradation by DNases in extracellular and intracellular
pathways, resulting in the enhancement of gene transfection
eﬃcacy. However, the cytotoxicity of cationic polymers is
an essential problem in the polyplex-based gene transfer
ﬁeld [6]. In addition, polymeric gene carriers may elicit2 Journal of Drug Delivery
nonspeciﬁc immune responses [7]. Therefore, signiﬁcant
eﬀorts have been made towards decreasing the toxicity of
polymeric gene carriers.
Two main strategies have been proposed to address this
issue. One is to attach polyethylene glycol (PEG), which
is widely used as a nonionic, highly soluble, low toxicity
polymer, to polymeric gene carriers, a process that is called
“PEGylation.” PEGylation increases the water solubility of
polyplexesandreducestheinteractionofpolyplexandserum
and blood components, resulting in eﬀective transfection
without toxicity [8, 9]. The other is the use of non- or less
cationic polymers, which can form complexes via nonelec-
trostatic interactions, such as hydrogen bonding. Double
strand schizophyllan, which is one type of polysaccharide
(β-1, 3 glucan), forms a triple helical complex with single-
strand DNA through hydrogen bonding interaction [10].
Protective interactive noncondensing (PINC)polymers, poly
(N-vinyl pyrrolidone) (PVP), and poly (vinyl alcohol)
(PVA), form ﬂexible polyplexes with DNA via hydrogen
bonds [11, 12]. In addition, we have developed a novel
formulation method of DNA complexes with nonionic,
water-soluble polymers through hydrogen bonding interac-
tion using high hydrostatic pressure technology. Under high
hydrostatic pressure conditions, inter- and intramolecular
hydrogen bonding interaction is eﬀectively formed [13–
15]. We previously reported that nanoscaled PVA/DNA
complexes via hydrogen bonding interaction were obtained
by high hydrostatic pressurization at 980MPa and 40◦Cf o r
10min [16]. The PVA/DNA nanoparticles were taken up
by RAW264 cells with nontoxicity, and no signiﬁcant gene
expressions were observed.
Traditionally, the calcium phosphate (Cap)-DNA copre-
cipitationmethodhasbeenusedforinvitro genetransfection
because of CaP’s biocompatibility, biodegradability, and
ease of handling [17, 18]. Many CaP-DNA coprecipitation
methods that particulate formation, being aﬀected by pH
[19], temperature [20], and buﬀer conditions [21], have
been developed to aim at eﬀective gene transfection. In
addition, several researchers have proposed the idea of
applying CaP-DNA coprecipitates produced in polyplexes to
gene delivery. It is considered that polyplexes including CaP
were internalized into cells through endocytosis pathways, in
which the pH was lower than 5.5, and then the rupture of
endosome and endosomal releases of polyplex were induced
by osmotic shock [22, 23]. Currently, nanoscaled HAps,
which are one of the forms of CaP, have been synthesized
with well-controlled size and shape and utilized as gene
carriers because of the capability of HAps to absorb DNA
molecules [24].
On the basis of this background, in the current study,
we used nanoscaled HAps (about 50nm) as an endosomal
escape reagent because of their ability to dissolve in endo-
some vesicles under low pH conditions. We investigated a
method ofpreparing thePVA/DNAcomplexesencapsulating
HAps by using high hydrostatic pressure technology in
detail. Using the obtained PVA/HAp/DNA nanoparticles,
the cellular uptake, cytotoxicity, and in vitro and in vivo
transfection eﬃciency were examined to aim at eﬀective and
safe gene transfection.
2.Materialsand Methods
2.1. Materials. PVA with a degree of polymerization of
1700 and a degree of saponiﬁcation of 99.3% was kindly
supplied from Kuraray Co. Ltd. (Osaka, Japan). HApwith an
average diameter of 50nm was synthesized by an emulsion
system [25, 26] and then suspended in water. Plasmid DNA
encoding a luciferase gene under an SV40 promoter (pGL3:
5.2 kbp) was purchased from Promega Co., Ltd., (Madison,
USA).
2.2. Preparation of PVA/HA/pDNA Complexes. An aqueous
PVA solution of 5 w/v% was prepared by autoclaving it
three times for 30 min at 121◦C and diluting it to various
concentrations. An aqueous HAp suspension prepared by
ultrasonication was added to the PVA solution. The DNA
solution was mixed with the PVA/HAp suspension (ﬁnal
concentrations: PVA 0.001–1.0 w/v%, HA 0.0001–0.1 w/v%,
DNA 0.0025 w/v%). The mixture solution of PVA, Hap,
and DNA was hydrostatically pressurized at 980MPa and
40◦C for 10min using a high hydrostatic pressure machine
(Dr. Chef: Kobe steel, Kobe, Japan).
2.3. Characterization of PVA/HAp/DNA Complexes. The
shapes of PVA/DNA (PVA: 1.0w/v%) and PVA/HAp/DNA
(PVA: 1.0w/v%, HAp: 0.1w/v%) complexes obtained by
the high hydrostatic pressurization were observed with
a scanning electron microscope (SEM, JSM-6301F, JEOL
Co., Tokyo, Japan). One μL of the complex solutions was
dropped on a glass slide and dried in air. The sizes of
the PVA/DNA and PVA/HAp/DNA complexes obtained
by the high hydrostatic pressurization were measured by
dynamic light scattering (DLS) using a Zetasizer Nano
product (Malvern, Worcestershire, UK). The stability of
DNA in PVA/DNA complex on 10% serum condition
was investigated. The PVA/DNA complexes were incubated
with medium containing 10% serum for 20h. Then, they
were subjected to in vitro transcription and translation
system (TNT Quick coupled Transcription/Translation Sys-
tem, Promega Co., Ltd., Madison, USA), and the luciferase
activity was measured by using an AB-2200 luminometer
(ATTO, Corp., Tokyo, Japan) for 10s.
2.4. Cytotoxicity of PVA/HAp/DNA Complexes. Am i x t u r e
solution of PVA (2w/v%) and HAp (0.2w/v%) was prepared
and diluted stepwise to 0.01w/v% of PVA and 0.001w/v% of
HAp. An aqueous DNA solution of 0.005w/v% was mixed
with PVA/HAp mixtures for each concentration at an equal
volume. Their mixtures were treated under 980MPa at 40
oC
for 10min using a high hydrostatic pressure machine. The
COS-7 cells used were purchased from RIKEN Bioresource
Center (BRC, Saitama, Japan). They were cultured in a
complete modiﬁed eagle medium (DMEM, Life technolo-
gies Japan Ltd, Tokyo, Japan), supplemented with non-
inactivated 10% fetal bovine serum (FBS), 50IU/mL of
penicillin, and 50μg/mL of streptomycin (ICN Biomaterials,
Ohio, USA). The COS-7 cells (2.0×104) on a 96-well
plate were incubated with PVA/DNA and PVA/HAp/DNA
complexes of various concentrations at 37◦Cf o r2 0 hi nJournal of Drug Delivery 3
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Figure 1: SEM images of (a) PVA/DNA complex (PVA: 1.0w/v%) and (b) PVA/HAp/DNA complex (PVA: 1.0w/v%, HAp: 0.1w/v%)
obtained by high hydrostatic pressurization (980MPa, 10min, 40◦C). DNA conc.: 0.0025w/v%.
thepresence of FBS(10%).The cellularviability was assessed
using a Cell Counting Kit-8 (Dojindo Laboratory, Tokyo,
Japan) according to the manufacturer’s instructions.
2.5.Cellular Uptake ofPVA/HAp/DNAComplexes. ThepGL3
plasmid DNA was labeled with rhodamine using a Label
It kit (Panvera, Wis, USA) according to the manufacturer’s
instructions (Rh-DNA). HAp/Rh-DNA (HAp: 0.4w/v%).
PVA/Rh-DNA, and PVA/HAp/Rh-DNA complexes (PVA:
0.001w/v%, HAp: 0.0001w/v%) were added to COS-7 cells
(1.0×105) cultured in 24-well plates in the presence of
FBS (10%), and incubated at 37◦C for one and 24h. After
washing with PBS twice, the cells were observed under a
ﬂuorescent microscope.
2.6. In Vitro Transfection. COS-7 cells (8.0×104)w e r e
cultured overnight in a 48-well plate. HAp/DNA (HAp:
0.4w/v%), PVA/DNA,and PVA/HAp/DNAcomplexes(PVA:
0.001w/v%, HAp: 0.0001w/v%) were added to cells and
incubated at 37◦C for 24h. The medium was removed from
each well and washed with PBS twice. 50μLo fa1 xl u c i f e r a s e
cell culture lysis buﬀer (Promega Co., Ltd., Madison, USA)
wasadded ontocells. Forluciferaseassay, 10μLo fc e l le x tra ct
was mixedwith 100μL of a luciferaseassay reagent (Promega
Co., Ltd., Madison, USA) and the luciferase activity was
measured by using an AB-2200 luminometer (ATTO, Corp.,
Tokyo, Japan) for 10s. The protein concentration of the
supernatant was determined by using a DC protein assay
kit (Bio-Rad laboratories, Inc., USA) according to the
manufacturer’s instructions.
2.7. In Vivo Transfection Using Hydrodynamic Injection
Method. 1.6mL of the saline solution of PVA/DNA and
PVA/HAp/DNA complexes (PVA: 0.001w/v% or 0.01w/v%,
HAp: 0.0001w/v% or 0.001w/v%, DNA: 0.0025w/v%) were
prepared by high hydrostatic pressurization and injected
by a hydrodynamic technique as previously described [27].
Brieﬂy, mice were restrained, and the tail vein was accessed
with a 25 gauge needle. Administration of the solution was
performed in 10 seconds or less without extravasation; each
group was represented by three or more animals. After 12,
24, and 72h injection, the liver and lung were dissected
from dead animals using the standard surgical procedures.
1mLoflysisbuﬀer (0.1M Tris-HCl, 2mM EDTA, and 0.1%
Triton X-100, pH 7.8) was added to a piece of liver with wet
weight of approximately 200mg. The liver was homogenized
for 15–20s with a homogenizer (PT2100, KINEMATICA
AG, Lucerne, Switzerland) at maximal speed, and the tissue
homogenate was then centrifuged in a microcentrifuge for
10min at 13000g at 4◦C. The protein concentration of the
supernatant was determined by using a DC protein assay
kit. For luciferase assay of the liver extract, the supernatant
was further diluted 60-fold using an HEPES buﬀer. 10μLo f
supernatant of diluted liver extract was mixed with 100μL
of luciferase assay reagent, and the luciferase activity was
measured by using the AB-2200 luminometer for 10s.
2.8. Statistical Analysis. All experiments were repeated at
least three times (ﬁve times for DLS analysis), and the values
are expressed as means ± standard deviations. Statistical
analysis was performed using student’s t-test, with the
signiﬁcant level set at P<. 05.
3.Resultsand Discussion
3.1. Preparation and Characterization of PVA/HAp/DNA
Complexes. The mixture solution of PVA, Hap, and DNA
was hydrostatically pressurized at 980MPa and 40◦Cf o r
10min using a high hydrostatic pressure machine. After
removal ofpressure, the obtained PVA/HAp/DNAcomplexes
were observed by SEM. Figure 1 shows typical SEM images
of PVA/DNA (PVA: 1.0%) and PVA/HAp/DNA complexes
(PVA: 1.0%, HAp: 0.1%). Many particles less than 1μm
were observed for the PVA/DNA complex. The surface of
PVA/DNA particles was smooth. On the other hand, in
the case of PVA/HAp/DNA complexes, irregular particle
surfaces were observed without any signiﬁcant HAp absorp-
tion on the particles, showing that HAp particles were4 Journal of Drug Delivery
Table 1:DLSmeasurementofPVA/DNAandPVA/HAp/DNAcomplexes atvariousPVAandHApconcentrations.DNA conc.:0.0025w/v%.
HAp (%) Average diameter (nm) (PDI) PVA (%)
0.001 0.005 0.01 0.05 0.1
0 306 ± 7 (0.08 ± 0.02) 325 ± 8 (0.13 ± 0.02) 360 ± 11 (0.16 ± 0.02) 525 ± 16 (0.07 ± 0.03) 649 ± 65 (0.11 ± 0.02)
0.00001 346 ± 4 (0.12 ± 0.02) 393 ± 8 (0.13 ± 0.02) 355 ± 14 (0.20 ± 0.02) 602 ± 17 (0.08 ± 0.03) 756 ± 17 (0.12 ± 0.03)
0.0001 358 ± 3 (0.11 ± 0.03) 397 ± 8 (0.10 ± 0.03) 390 ± 8 (0.19 ± 0.01) 649 ± 21 (0.12 ± 0.03) 770 ± 20 (0.08 ± 0.03)
0.0005 571 ± 34 (0.24 ± 0.13) 572 ± 27 (0.15 ± 0.03) 689 ± 17 (0.05 ± 0.03) 1090 ± 44 (0.21 ± 0.03)
0.001 578 ± 42 (0.278 ± 0.04) 684 ± 14 (0.11 ± 0.21) 785 ± 21 (0.11 ± 0.02) 1080 ± 21 (0.25 ± 0.02) 1310 ± 59 (0.23 ± 0.03)
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Figure 2: DLS measurement of PVA/DNA and PVA/HAp/DNA
complexes at various PVA and HAp concentrations. DNA conc.:
0.0025w/v%. Each value represents the mean ± SD (n = 5).
encapsulated in the PVA/HAp/DNAcomplexes. When excess
HAps were mixed with PVA and DNA, many aggregates
of HAps on the PVA/HAp/DNA particles obtained by the
pressurization were clearly visible (data not shown). The
particle size of PVA/DNA and PVA/HAp/DNA complexes
at various concentrations of PVA and HAp were measured
by DLS measurement (Figure 2, Table 1). The diameter of
PVA/DNA particles without HAp increased with increased
PVA concentration, which corresponds to our previous
report [1–4]. This tendency was exhibited for the particle
size of PVA/HAp/DNA complexes, irrespective of HAp
concentration. At each PVA concentration, the diameter
of PVA/HAp/DNA particles increased with increased HAp
concentration, indicating that HAp particles were signiﬁ-
cantly encapsulated in PVA/HAp/DNA complexes at these
concentrations of PVA and HAp. From these results of
SEM observation and DLS measurement, it was clear that
nano-, microscaled composites of PVA, Hap, and DNA were
obtained by high hydrostatic pressurization, and the size
of PVA/HAp/DNA particles depended on PVA and HAp
concentrations. To investigate the stability of DNA in the
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Figure 3: Stability of DNA in PVA/DNA complexes in the presence
of serum. Each value represents the mean ± SD (n = 3). ∗P<. 05.
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Figure4:ViabilityofCOS-7cellsincubatedwith(white)PVA/DNA
complexes and (black) PVA/HAp/DNA complexes for 24 h. DNA
conc.: 0.0025w/v%. Each value represents the mean ± SD (n = 3).
PVA/DNA particles on serum condition, PVA/DNAparticles
were incubated in medium containing 10% serum for 20h,
and then subjected to in vitro transcription and translation
(Figure 3). The high luciferase activity of DNA was showed
on the condition without serum, whereas the luciferase
activitywasremarkablyreducedafterincubationwithserum.Journal of Drug Delivery 5
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Figure 5: Fluorescent microscopic images of COS-7 cells incubated with (a, e) DNA, (b, f) HAp/DNA complex, (c, g) PVA/DNA complex,
and (d, h) PVA/HAp/DNA complex for (a–d) 1h and (e–h) 24h. Scale bars are 10μm.
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Figure 6: In vitro transfection using HAp/DNA, PVA/DNA and
PVA/HAp/DNA complexes. Each value represents the mean ± SD
(n = 3). ∗P<. 05.
On the other hand, there is no diﬀerence in the luciferase
activity of DNA in PVA/DNA particles before and after
incubation with serum, indicating the high stability of DNA
in PVA/DNA particles against serum.
To date, many methods for preparation of composite
materials of PVA and HAp, such as in situ crystallization of
HAp in PVA hydrogel [28], gelation of PVA solution mixed
with HAp crystals [29], and alternating soaking reaction,
which promote HAp crystallization on/in gel [30], have
been reported. Large-scaled composite hydrogels (several
centimeters) have been prepared for use in biomedical appli-
c a t i o n ss u c ha sc a r t i l a g ea n db one. However, few preparation
methods of nanocomposites of PVA and Hap have been
reported. In this study, the nano-, microparticles of PVA,
HAp and DNA were obtained by using high hydrostatic
pressure technology. It is thought that this is achieved by
the pressure-induced quick formation of PVA particles that
could incorporate secondary and third substrates, such as
DNA and HAp, without phase separation [15, 31].
3.2. Cytotoxicity Test. Figure 4 shows the result of the cyto-
toxicity test of PVA/DNA and PVA/HAp/DNA complexes.
The high viability of COS-7 cells incubated with them is
shown, irrespective of the concentration of PVA and HAp.
PVA and HAp are biocompatible materials [32, 33]. The
PVA/DNA complex is nontoxic because of the composite
formation of PVA and DNA via hydrogen bonding inter-
action [16]. HAps were encapsulated in PVA/HAp/DNA
complexes. Consequently, it is considered that the nontox-
icity of PVA/HAp/DNA complexes was achieved by these
combinations.
3.3. Cellular Uptake of PVA/HAp/DNA Nanoparticles. In
order to investigate cellular uptake of the HAp/DNA
complex, PVA/DNA, and PVA/HAp/DNA nanoparticles,
rhodamine-labeled plasmid DNA was used. Figure 4 shows
ﬂuorescent microscopic images of COS-7 cells incubated
with complexes of PVA, Hap, and rhodamine-labeled DNA
for one and 24h. After 1h incubation, ﬂuorescent spots
were poorly observed for DNA and PVA/DNA nanopar-
ticles (Figures 5(a) and 5(c)), whereas a lot of bright red6 Journal of Drug Delivery
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Figure 7: Transgene expression (luciferase activity) of plasmid DNA, PVA/DNA, and PVA/HAp/DNA complexes injected by in vivo
hydrodynamic method. (b) Time course of transgene expression of plasmid DNA and PVA/HAp/DNA complexes injected by in vivo
hydrodynamic method. Each value represents the mean ± SD (n = 3). ∗P<. 05.
ﬂuorescent spots on many cells were shown in the case
of HAp/DNA and PVA/HAp/DNA complexes (Figures 5(b)
and 5(d)), indicating the eﬀective absorption of them onto
cells because of their higher speciﬁc gravity. However,
strong aggregation of HAp/DNA complexes was observed
due to the fact that the nature of HAp particles tends
to result in an aggregation in the aqueous medium [34].
For PVA/HAp/DNA nanoparticles, PVA bearing HAp could
attenuate the aggregation property of HAp. After 24h
incubation, the aggregation of the HAp/DNA composite
was still observed (Figure 5(f)). The internalization of
PVA/HAp/DNA nanoparticles into cells was exhibited. Also,
the subcellular distribution of DNA was observed in some
cells (Figure 5(h)) similar to that of PVA/DNA nanoparticles
(Figure 5(g)). This strongly suggests that HAp in PVA/HAp/
DNA nanoparticles could be dissolved during the intracellu-
lar process, probably due to the endocytosis pathway.
3.4. In Vitro Transfection Using PVA/HAp/DNA Nanopar-
ticles. The expressing of the delivered DNA compositing
with PVA and HAp was assayed by measuring luciferase
activity (Figure 6). Low luciferase activity was shown for the
HAp/DNA complex. This is caused by the strong aggrega-
tion of HAp/DNA complexes [20]. The level of luciferase
activity of PVA/DNA nanoparticles was similar to that of
the HAp/DNA complex due to the slow internalization of
PVA/DNA nanoparticles into cells, which could probably
permit DNA degradation. In the case of the PVA/HAp/DNA
nanoparticles, which can be taken up by cells quickly,
high luciferase activity was shown, indicating that the
encapsulation of HAp in PVA/DNA nanoparticles could
enhance the transfection eﬃciency in vitro. However, the
transection eﬃciency of the PVA/HAp/DNA nanoparticles
waslowerthaninthehigh-eﬃcientcalciumphosphatetrans-
fection method, which is optimized for in vitro transfection
[21].
3.5. In Vivo Transfection Using Hydrodynamic Injection. In
vivo transfection was performed by using a hydrodynamic
method (Figure 7). This method is known as an eﬀective
plasmid DNA transfection method without gene carrier to
liver [35]. Figure 7(a) shows the results of in vivo hydrody-
namic injection using various nanoparticles. The luciferase
activity of the PVA/DNA complex (PVA: 0.001w/v%) was
lower than that of DNA injection, whereas high luciferase
activity was achieved for PVA/HAp/DNA nanoparticles at
the PVA concentration of 0.001w/v% (HAp: 0.0001w/v%).
At PVA concentration of 0.01w/v% (HAp: 0.001w/v%), the
luciferaseactivityofPVA/HAp/DNAnanoparticlesdecreased
compared to that of 0.001w/v%. This is thought to be
caused by the insigniﬁcant uptake of the large particles
of PVA/HAp/DNA nanoparticles (about 780nm, Figure 2,
Table 1) by hepatocytes [36]. When the luciferase activity
in lung was also investigated, the low activity was detected
in lung compared to that in liver, irrespective of type of
nanoparticles.
The time-course of transgene activity was also investi-
gated (Figure 7(b)). For plasmid DNA, the highest value for
luciferase activity was detected after 12 hours, and the level
of gene expression signiﬁcantly decreased over time. On the
other hand, in the case of PVA/HAp/DNAnanoparticles, the
highestvalueforluciferaseactivitywasachievedfor24hours.Journal of Drug Delivery 7
This result indicates that the PVA/HAp/DNA nanoparticles
could prolong the gene expression. We assumed that PVA/
HAp/DNA nanoparticles could be accumulated due to the
relative high stability, which are continuously transcribed
and translated (Figure 3).
4.Conclusion
We successfully developed PVA/DNA nanoparticles encap-
sulating HAps by using simple high hydrostatic pressure
technology. They could enhance the transfection eﬃciency
without any signiﬁcant cytotoxicity in vitro and in vivo
hydrodynamic injection. Consequently, the potential use of
HAp could be expected as an enhancer of gene transfer
activity of PVA/DNA nanoparticles.
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